The study was designed to evaluate the efficacy and safety of SHR-1826 monotherapy or in combination with immunotherapy in the treatment of advanced hepatocellular cancer patients.
None
Known or suspected to have a severe allergic history to the drugs related to this study (including drugs of the same type);
Evidence of liver decompensation: including but not limited to symptomatic ascites, esophageal-gastric variceal bleeding, hepatic encephalopathy, hepatorenaHave central nervous system metastasis;l syndrome, sepsis, etc.;
Have central nervous system metastasis;
Have a history of organ transplantation or are preparing for organ transplantation (including but not limited to liver transplantation);